clinical trialBiotech

Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer

Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer (NCT03976843)

updatedDate Venue ClinicalTrials.gov

Source-permitted summary

Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer | Phase: PHASE2 | Conditions: Prostate Cancer

SourceClinicalTrials.gov

Verified by AISci

Public source attached

Source status for this paper in the current AISci reviewed snapshot.

Primary source
ClinicalTrials.gov
Correction status
none
Evidence coverage
1 sources / 1 publishers
Last metadata check
Jul 19, 2026
Open primary source

AI Reading Notes

Core signal

Structured notes generated from source-linked AISci metadata. Treat them as a reading aid, not a substitute for the paper.

Core signal
Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer | Phase: PHASE2 | Conditions: Prostate Cancer
Field context
Protein and Drug Design
People and labs
Not stated in the reviewed source.
Why it matters
Clinical trial registry updates are translation signals, not commercialization claims by themselves.
Limits to check
ClinicalTrials.gov status does not prove product approval, licensing, revenue, or market adoption.

Publication facts

Type
clinical trialSourceClinicalTrials.gov
Date
Jul 16, 2026SourceClinicalTrials.gov
Venue
ClinicalTrials.govSourceClinicalTrials.gov

External IDs

Author order

No reviewed author edge is attached to this output.

Organizations

No source-confirmed author affiliation is attached.

Related events

Topics

Relationship evidence

Timeline

  1. clinical trialProstate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer